Internal Medicine, Endocrinology, Diabetes, & Metabolism · Webster, TX
NPI
1417996109
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
600 N Kobayashi Ste 312
Webster, TX, 77598
Phone (281) 724-8333
Groups this clinician bills Medicare through
Medicare paid, 2024
$262K
10,543 services
Medicare patients, 2024
785
Average age 73
Drug cost, 2024
$6.0M
11,312 prescriptions
Company payments, 2025
$3,544
From 32 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Charlie C Chang was code J0897 (injection, denosumab, 1 mg), 3,483 times for 43 patients. In total Charlie C Chang billed 10,543 services in 29 codes, and Medicare paid $262K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 3,483 | 43 | $20.62 | $72K |
| 99214 Office E&M - Established | Office | 1,080 | 571 | $89.96 | $97K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 298 | 252 | $12.77 | $3,807 |
| 99213 Office E&M - Established | Office | 151 | 137 | $63.48 | $9,585 |
| 96401 Chemotherapy Administration | Office | 107 | 45 | $52.92 | $5,662 |
| 99233 Hospital E&M - Subsequent | Facility | 91 | 46 | $93.52 | $8,510 |
| 99204 Office E&M - New | Office | 81 | 81 | $112.94 | $9,148 |
| 99223 Hospital E&M - Initial | Facility | 51 | 46 | $135.06 | $6,888 |
| 76536 Ultrasound - Nonspecific | Office | 23 | 23 | $73.06 | $1,680 |
| 95251 Test - Miscellaneous | Office | 15 | 15 | $23.91 | $359 |
| 99232 Hospital E&M - Subsequent | Facility | 15 | 13 | $58.44 | $877 |
| 99203 Office E&M - New | Office | 12 | 12 | $89.85 | $1,078 |
| 96365 Intravenous Infusion, Hydration | Office | 11 | 11 | $40.51 | $446 |
By year: 2022 $284K for 15,190 services; 2023 $271K for 13,087 services; 2024 $262K for 10,543 services.
Medicare prescription drug claims, 2024
In 2024, the drug Charlie C Chang prescribed most often to Medicare patients was Ozempic (Semaglutide), with 899 prescriptions and refills. In total Charlie C Chang wrote 11,312 Medicare prescriptions that cost $6.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 899 | 1,472 | 222 | $1.3M |
| Levothyroxine Sodium Generic | 790 | 2,202 | 267 | $9,504 |
| Metformin Hcl Generic | 469 | 1,359 | 165 | $3,304 |
| Synthroid Levothyroxine Sodium | 449 | 1,161 | 130 | $41K |
| Metformin Hcl Er Metformin Hcl | 407 | 1,114 | 145 | $5,291 |
| Jardiance Empagliflozin | 364 | 844 | 109 | $468K |
| Pioglitazone Hcl Generic | 298 | 800 | 92 | $4,611 |
| Atorvastatin Calcium Generic | 281 | 841 | 102 | $2,787 |
| Mounjaro Tirzepatide | 275 | 382 | 76 | $392K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 270 | 748 | 139 | $35K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 266 | 742 | 107 | $49K |
| Tresiba Flextouch U-100 Insulin Degludec | 233 | 576 | 84 | $180K |
| Liothyronine Sodium Generic | 184 | 523 | 60 | $6,518 |
| Gabapentin Generic | 172 | 414 | 67 | $2,811 |
| Glipizide Generic | 168 | 484 | 65 | $1,937 |
Brand drugs: 5,320 claims; generic drugs: 5,185 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Charlie C Chang $3,544 ($3,544 in general payments such as food, travel and fees) from 32 companies. The largest payer was Insulet Corporation with $428.
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation PODD | 7 | $428 |
| Novo Nordisk Inc NVO | 19 | $392 |
| Ascendis Pharma Endocrinology Inc ASND | 17 | $322 |
| Corcept Therapeutics CORT | 15 | $253 |
| Recordati_rare_diseases_inc. | 14 | $248 |
| Amgen Inc. AMGN | 19 | $176 |
| Abbvie Inc. ABBV | 12 | $160 |
| Mannkind Corporation MNKD | 14 | $158 |
| Beta Bionics, Inc. BBNX | 3 | $148 |
| OPKO Pharmaceuticals, LLC | 9 | $143 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.